Update on the Management of Diabetic Neuropathy
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
IN BRIEF Distal symmetric polyneuropathy (DSPN) and diabetic autonomic neuropathies, particularly cardiovascular autonomic neuropathy (CAN), are prevalent diabetes complications with high morbidity, mortality, and amputation risks. The diagnosis of DSPN is principally a clinical one based on the presence of typical symptoms combined with symmetrical, distal-to-proximal stocking-glove sensory loss. CAN is an independent risk factor for cardiovascular mortality, arrhythmia, silent ischemia, major cardiovascular events, and myocardial dysfunction. Screening for CAN in high-risk patients is recommended. Symptoms of gastroparesis are nonspecific and do not correspond with its severity. Diagnosis of gastroparesis should exclude other factors well documented to affect gastric emptying such as hyperglycemia, hypoglycemia, and certain medications. There is a lack of treatment options targeting the neuropathic disease state. Managing neuropathic pain also remains a challenge. Given the high risk of addiction, abuse, psychosocial issues, and mortality, opioids are not recommended as first-, second-, or third-line agents for treating painful DSPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Persons with prediabetes and/or obesity may also develop DPN.547,548,553”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [553]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“However, a multifactorial intervention that included a lifestyle component and targeted glucose and cardiovascular disease risk factors reduced the risk of CAN by 60% in people with type 2 diabetes (1,45).”
BackgroundGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 8×
“Tramadol and other opioids have also shown some efficacy on DSPN pain in large multicenter trials (1,49,58).”
BackgroundResultInfluentialDiabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 15×
“DSPN affects primarily the sensory nerves, and the symptoms and signs vary according to the type of sensory fibers involved (1,5).”
BackgroundSelf-citationYoung, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502 · cited 1×
“Contemporary prevalence rates for DSPN remain high, occurring in at least 20% of people with type 1 diabetes of >20 years’ duration (1,6,7), 10–15% of people with newly diagnosed type 2 diabetes (1,8,9), and 10–30% of subjects with impaired glucose tolerance (IGT) or metabolic syndrome (1,3,4).”
BackgroundIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · cited 1×
“In contrast, enhanced glucose control in people with type 2 diabetes reduces the risk of developing DSPN modestly (5–9% relative risk reduction) (41,42) and selectively (10,43).”
BackgroundSelf-citationDiabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211 · cited 2×
“This discrepancy highlights the difference between type 1 and type 2 diabetes and emphasizes the point that many people with type 2 diabetes develop DSPN despite adequate glucose control (10,41), likely because of asymptomatic hyperglycemia for many years before the diagnosis of type 2 diabetes, the presence of multip…”
BackgroundAllodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms
Jensen, T. S., & Finnerup, N. B. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70102-4 · Cited by 976 · cited 2×
“Neuropathic pain may be present in 25–50% of individuals with DSPN and may be the first symptom that prompts patients to seek medical care (1,13,14).”
BackgroundNew Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915 · cited 17×
“DSPN affects primarily the sensory nerves, and the symptoms and signs vary according to the type of sensory fibers involved (1,5).”
BackgroundInfluentialAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Dabelea, D., Stafford, J. M., Mayer-Davis, E. J., D’Agostino, R., Dolan, L., Imperatore, G., Linder, B., Lawrence, J. M., Marcovina, S. M., Mottl, A. K., et al. (2017) · JAMA · doi:10.1001/jama.2017.0686 · Cited by 700
Self-citationTesfaye, S., Stevens, L. K., Stephenson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., Nuber, A., Pozza, G., & Ward, J. D. (1996) · Diabetologia · doi:10.1007/s001250050586 · Cited by 695 · cited 1×
“Contemporary prevalence rates for DSPN remain high, occurring in at least 20% of people with type 1 diabetes of >20 years’ duration (1,6,7), 10–15% of people with newly diagnosed type 2 diabetes (1,8,9), and 10–30% of subjects with impaired glucose tolerance (IGT) or metabolic syndrome (1,3,4).”
BackgroundBril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1895 · Cited by 578
Pop-Busui, R., Evans, G. W., Gerstein, H. C., Fonseca, V., Fleg, J. L., Hoogwerf, B. J., Genuth, S., Grimm, R. H., Corson, M. A., Prineas, R., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0125 · Cited by 540
Self-citationMoulin, D., Boulanger, A., Clark, A., Clarke, H., Dao, T., Finley, G., Furlan, A., Gilron, I., Gordon, A., Morley-Forster, P., et al. (2014) · Pain Research and Management · doi:10.1155/2014/754693 · Cited by 529
Martin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2114 · Cited by 499 · cited 4×
“There is also robust evidence for CAN prevention with intensive glucose control designed to achieve near-normal glycemia in type 1 diabetes (11), as documented by a 45% reduction in the risk of incident CAN, assessed with highly reproducible and sensitive tests in a large sample during the Diabetes Control and Complic…”
BackgroundSelf-citationExercise training can modify the natural history of diabetic peripheral neuropathy
Balducci, S., Iacobellis, G., Parisi, L., Di Biase, N., Calandriello, E., Leonetti, F., & Fallucca, F. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.07.005 · Cited by 427
Ziegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., Mielck, A., & for the KORA Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1796 · Cited by 397 · cited 2×
“High prevalence rates for CAN were recently reported in a large cohort of youths with type 1 or type 2 diabetes (2) and in patients with IGT or the metabolic syndrome (4,26).”
BackgroundChanges in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016
Jones, C. M., Einstein, E. B., & Compton, W. M. (2018) · JAMA · doi:10.1001/jama.2018.2844 · Cited by 361 · cited 1×
“Mortality rates associated with overdoses of prescription opioids in the United States have more than quadrupled and have reached the level of a true epidemic (1,59).”
BackgroundNeuropathy among the diabetes control and complications trial cohort 8 years after trial completion
Martin, C. L., Albers, J., Herman, W. H., Cleary, P., Waberski, B., Greene, D. A., Stevens, M. J., & Feldman, E. L. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1549 · Cited by 350 · cited 1×
“Combining at least two examinations is associated with higher sensitivity and specificity in detecting DSPN in patients with either type 1 or type 2 diabetes (1,20,21).”
BackgroundFreeman, R., Durso-DeCruz, E., & Emir, B. (2008) · Diabetes Care · doi:10.2337/dc07-2105 · Cited by 322
Pop-Busui, R., Low, P. A., Waberski, B. H., Martin, C. L., Albers, J. W., Feldman, E. L., Sommer, C., Cleary, P. A., Lachin, J. M., & Herman, W. H. (2009) · Circulation · doi:10.1161/circulationaha.108.837369 · Cited by 310
Self-citationNot Available, N. A. (1998) · Diabetologia · doi:10.1007/s001250050924 · Cited by 308 · cited 1×
“Cardiovascular Autonomic Neuropathy The prevalence of CAN is very low in newly diagnosed patients with type 1 diabetes (24), but increases substantially with diabetes duration (1,10) up to 30% after 20 years of diabetes (7,25); in type 2 diabetes, the prevalence is up to 50% after 15 years of diabetes (1).”
BackgroundGlucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials
Ang, L., Jaiswal, M., Martin, C., & Pop-Busui, R. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0528-7 · Cited by 303 · cited 5×
“In contrast, enhanced glucose control in people with type 2 diabetes reduces the risk of developing DSPN modestly (5–9% relative risk reduction) (41,42) and selectively (10,43).”
BackgroundSelf-citationDiabetic Peripheral Neuropathy and Depressive Symptoms
Vileikyte, L., Leventhal, H., Gonzalez, J. S., Peyrot, M., Rubin, R. R., Ulbrecht, J. S., Garrow, A., Waterman, C., Cavanagh, P. R., & Boulton, A. J. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2378 · Cited by 288 · cited 1×
“This pain can lead to interference with daily activities, disability, psychosocial impairment, reduced health-related quality of life (15,16), and substantial economic burden (1).”
BackgroundAmitriptyline for neuropathic pain in adults
Moore, R. A., Derry, S., Aldington, D., Cole, P., & Wiffen, P. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008242.pub3 · Cited by 286 · cited 1×
“Several randomized, blinded, placebocontrolled clinical trials reported significant improvement in neuropathic pain (1), although a recent Cochrane review questioned the quality of evidence, raising concerns about bias given the small sample sizes of most of these trials (55).”
BackgroundDCCT Research Group, B. N. (1995) · Annals of Neurology · doi:10.1002/ana.410380607 · Cited by 283 · cited 1×
“Glucose Control Enhanced glucose control in people with type 1 diabetes dramatically reduces the incidence of DSPN (78% relative risk reduction) (39,40).”
BackgroundThe Development and Validation of a Neuropathy- and Foot Ulcer-Specific Quality of Life Instrument
Vileikyte, L., Peyrot, M., Bundy, C., Rubin, R. R., Leventhal, H., Mora, P., Shaw, J. E., Baker, P., & Boulton, A. J. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2549 · Cited by 274 · cited 1×
“Two neuropathyspecific research tools that can be used to assess quality of life are the NeuroQol (22) and the Norfolk QOL-DN (23) instruments.”
MethodRisk of gastroparesis in subjects with type 1 and 2 diabetes in the general population
Choung, R. S., Locke, R. G., Schleck, C. D., Zinsmeister, A. R., Melton, J. L., & Talley, N. J. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.310 · Cited by 266 · cited 1×
“In the only community-based study, the cumulative incidence of gastroparesis over 10 years was higher in people with type 1 diabetes (5%) than in those with type 2 diabetes (1%) or control subjects (1%) (38).”
BackgroundSchwartz, S., Etropolski, M., Shapiro, D. Y., Okamoto, A., Lange, R., Haeussler, J., & Rauschkolb, C. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.537589 · Cited by 262 · cited 1×
“Two multicenter, randomized-withdrawal, placebo-controlled phase 3 trials reported efficacy in DSPN pain reduction (56,57), leading to FDA approval for the treatment of DSPN pain.”
BackgroundRelationship Between Risk Factors and Mortality in Type 1 Diabetic Patients in Europe
Soedamah-Muthu, S. S., Chaturvedi, N., Witte, D. R., Stevens, L. K., Porta, M., Fuller, J. H., & for the EURODIAB Prospective Complications Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0107 · Cited by 237
Vinik, E. J., Hayes, R. P., Oglesby, A., Bastyr, E., Barlow, P., Ford-Molvik, S. L., & Vinik, A. I. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.497 · Cited by 235 · cited 1×
“Two neuropathyspecific research tools that can be used to assess quality of life are the NeuroQol (22) and the Norfolk QOL-DN (23) instruments.”
MethodQuilici, S., Chancellor, J., Löthgren, M., Simon, D., Said, G., Le, T. K., Garcia-Cebrian, A., & Monz, B. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-6 · Cited by 223 · cited 1×
“Several clinical trials have shown its efficacy in doses of 1,800–3,600 mg for treating the pain associated with DSPN (49,52,54).”
BackgroundCarnethon, M. R., Prineas, R. J., Temprosa, M., Zhang, Z.-M., Uwaifo, G., Molitch, M. E., & for the Diabetes Prevention Program Research Group (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1729 · Cited by 220 · cited 1×
“High prevalence rates for CAN were recently reported in a large cohort of youths with type 1 or type 2 diabetes (2) and in patients with IGT or the metabolic syndrome (4,26).”
BackgroundCallaghan, B. C., Xia, R., Banerjee, M., de Rekeneire, N., Harris, T. B., Newman, A. B., Satterfield, S., Schwartz, A. V., Vinik, A. I., Feldman, E. L., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0081 · Cited by 220
Ziegler, D., Zentai, C. P., Perz, S., Rathmann, W., Haastert, B., Döring, A., Meisinger, C., & for the KORA Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1615 · Cited by 210
Lachin, J. M., Bebu, I., Bergenstal, R. M., Pop-Busui, R., Service, F. J., Zinman, B., Nathan, D. M., & for the DCCT/EDIC Research Group (2017) · Diabetes Care · doi:10.2337/dc16-2426 · Cited by 186
Self-citationAstrup, A. S., Tarnow, L., Rossing, P., Hansen, B. V., Hilsted, J., & Parving, H.-H. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1242 · Cited by 182
Griebeler, M. L., Morey-Vargas, O. L., Brito, J. P., Tsapas, A., Wang, Z., Carranza Leon, B. G., Phung, O. J., Montori, V. M., & Murad, M. H. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0511 · Cited by 178 · cited 2×
“Several clinical trials have shown its efficacy in doses of 1,800–3,600 mg for treating the pain associated with DSPN (49,52,54).”
BackgroundPop-Busui, R., Lu, J., Brooks, M. M., Albert, S., Althouse, A. D., Escobedo, J., Green, J., Palumbo, P., Perkins, B. A., Whitehouse, F., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0012 · Cited by 167 · cited 2×
“There is also robust evidence for CAN prevention with intensive glucose control designed to achieve near-normal glycemia in type 1 diabetes (11), as documented by a 45% reduction in the risk of incident CAN, assessed with highly reproducible and sensitive tests in a large sample during the Diabetes Control and Complic…”
BackgroundSelf-citationDiabetic Peripheral Neuropathy Compromises Balance During Daily Activities
Brown, S. J., Handsaker, J. C., Bowling, F. L., Boulton, A. J. M., & Reeves, N. D. (2015) · Diabetes Care · doi:10.2337/dc14-1982 · Cited by 161 · cited 3×
“Tests assessing gait and balance may be also considered in clinical practice to evaluate the risk of falls in patients who may be at risk, particularly in the elderly (17,18).”
BackgroundVinik, A. I., Shapiro, D. Y., Rauschkolb, C., Lange, B., Karcher, K., Pennett, D., & Etropolski, M. S. (2014) · Diabetes Care · doi:10.2337/dc13-2291 · Cited by 132 · cited 1×
“Two multicenter, randomized-withdrawal, placebo-controlled phase 3 trials reported efficacy in DSPN pain reduction (56,57), leading to FDA approval for the treatment of DSPN pain.”
BackgroundExercise increases cutaneous nerve density in diabetic patients without neuropathy
Singleton, J. R., Marcus, R. L., Jackson, J. E., K. Lessard, M., Graham, T. E., & Smith, A. G. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.125 · Cited by 127 · cited 2×
“However, a recent trial in patients with type 2 diabetes engaged in an exercise intervention reported reversal of DSPN as documented by nerve fiber regeneration compared to loss of nerve fibers in those who only followed standard care (47).”
BackgroundRelation between risk of falling and postural sway complexity in diabetes
Morrison, S., Colberg, S. R., Parson, H. K., & VINIK, A. I. (2012) · Gait & Posture · doi:10.1016/j.gaitpost.2011.12.021 · Cited by 121 · cited 4×
“Treatment of neuropathic pain often requires dosages and drug combinations that may further increase patients’ fall risk due to cognitive impairment, drowsiness, dizziness, blurred vision, and gait disturbances, particularly in older patients (1,17).”
BackgroundInfluentialPop-Busui, R., Braffett, B. H., Zinman, B., Martin, C., White, N. H., Herman, W. H., Genuth, S., Gubitosi-Klug, R., & the DCCT/EDIC Research Group (2017) · Diabetes Care · doi:10.2337/dc16-1397 · Cited by 116
Self-citationCharles, M., Ejskjaer, N., Witte, D. R., Borch-Johnsen, K., Lauritzen, T., & Sandbaek, A. (2011) · Diabetes Care · doi:10.2337/dc11-0903 · Cited by 111 · cited 1×
“In contrast, enhanced glucose control in people with type 2 diabetes reduces the risk of developing DSPN modestly (5–9% relative risk reduction) (41,42) and selectively (10,43).”
Ziegler, D., Duan, W. R., An, G., Thomas, J. W., & Nothaft, W. (2015) · Pain · doi:10.1097/j.pain.0000000000000263 · Cited by 99 · cited 1×
“However, not all trials with pregabalin have been positive (49,53), especially when treating advanced refractory patients, and others suggested a progressive response from 300 to 600 mg/day (1,51).”
BackgroundAssociation Between Cardiovascular Autonomic Neuropathy and Left Ventricular Dysfunction
Pop-Busui, R., Cleary, P. A., Braffett, B. H., Martin, C. L., Herman, W. H., Low, P. A., Lima, J. A. C., & Bluemke, D. A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.028 · Cited by 88
Self-citationBril, V., England, J. D., Franklin, G. M., Backonja, M., Cohen, J. A., Del Toro, D. R., Feldman, E. L., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Muscle & Nerve · doi:10.1002/mus.22092 · Cited by 87
Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance
Zilliox, L. A., Ruby, S. K., Singh, S., Zhan, M., & Russell, J. W. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.01.011 · Cited by 85 · cited 1×
“Combining at least two examinations is associated with higher sensitivity and specificity in detecting DSPN in patients with either type 1 or type 2 diabetes (1,20,21).”
BackgroundThe clinical use of the 10g monofilament and its limitations: A review
Tan, L. S. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.06.021 · Cited by 79 · cited 1×
“The 10-g monofilament test alone is useful for detecting more advanced neuropathy and identifying patients at increased risk of ulceration and amputation (1,19).”
BackgroundSommer, C., Welsch, P., Klose, P., Schaefert, R., Petzke, F. W., & Häuser, W. (2014) · Der Schmerz · doi:10.1007/s00482-014-1455-x · Cited by 76
Smith, A. G., & Singleton, J. R. (2012) · Continuum · doi:10.1212/01.con.0000411568.34085.3e · Cited by 58
Orlov, S., Cherney, D. Z. I., Pop-Busui, R., Lovblom, L. E., Ficociello, L. H., Smiles, A. M., Warram, J. H., Krolewski, A. S., & Perkins, B. A. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11441114 · Cited by 57
Self-citationZiegler, D., Strom, A., Lobmann, R., Reiners, K., Rett, K., & Schnell, O. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.09.008 · Cited by 48
Vinik, E. J., Silva, M. P., & Vinik, A. I. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.12.008 · Cited by 32 · cited 1×
“This pain can lead to interference with daily activities, disability, psychosocial impairment, reduced health-related quality of life (15,16), and substantial economic burden (1).”
BackgroundWheelock, K. M., Jaiswal, M., Martin, C. L., Fufaa, G. D., Weil, E. J., Lemley, K. V., Yee, B., Feldman, E., Brosius, F. C., Knowler, W. C., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.03.008 · Cited by 24
Self-citation
Research works printed but not linked: 1
- Jaiswal, 2014, Prevalence and correlates of cardiovascular autonomic neuropathy in youth with type 1 diabetes: SEARCH for Diabetes in Youth Study [Abstract], Diabetes, 63, A145
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationLu, Y., Xing, P., Cai, X., Luo, D., Li, R., Lloyd, C. E., Sartorius, N., & Li, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.534372 · Cited by 148
“As a major contributor to peripheral nerve injury (4), DPN impairs quality of life and potentiates risks of disability in diabetic subjects (5).”
BackgroundLin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Self-citationSpectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Dillon, B. R., Ang, L. P., & Pop‐Busui, R. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033114 · Cited by 103
Self-citationİzgü, N., Metin, Z. G., Karadaş, C., Özdemir, L., Metinarikan, N., & Çorapçıoğlu, D. (2020) · Journal of Nursing Scholarship · doi:10.1111/jnu.12580 · Cited by 78
Metadata
- Authors
- Ang, L., Cowdin, N., Mizokami-Stout, K., & Pop-Busui, R.
- Affiliations
- University of Michigan (US)
- Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
- ORCID
- Ang, Lynn
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2018-08-01
- Volume
- 31
- Issue
- 3
- Pages
- 224-233
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC6092893
- OpenAlex
- W2886645622
- Cited by
- 55
- References
- 61
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic neuropathy, distal symmetric polyneuropathy, diabetic autonomic neuropathy, cardiac autonomic neuropathy, gastroparesis, neuropathic pain, opioid use, amputation risk, cardiovascular mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.